Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma

Intravenous cytostatic agents as second‐line treatment of epithelial ovarian carcinoma have been withheld from many elderly patients because of fear of toxicity. The purpose of the study is to compare the toxicity and efficacy between elderly (older than 65 years of age) and younger (younger than 65 years of age) patients receiving intravenous second‐line treatment of epithelial ovarian carcinoma.

[1]  R. Barakat,et al.  Epithelial ovarian cancer in the elderly: The memorial sloan‐kettering cancer center experience , 2010 .

[2]  E. Kohn,et al.  Age does not influence taxol dose intensity in recurrent carcinoma of the ovary , 2010, Cancer.

[3]  M. Brady,et al.  Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experience , 2010, Cancer.

[4]  J. Krook,et al.  Treatment of ovarian cancer in elderly women: Mayo clinic–north central cancer treatment group studies , 2010, Cancer.

[5]  L. Ries,et al.  Ovarian cancer: Survival and treatment differences by age , 2010, Cancer.

[6]  H. Hansen,et al.  Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. , 2001, Gynecologic oncology.

[7]  H. V. van Houwelingen,et al.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Vermorken,et al.  Drug Therapy for Gynaecological Cancer in Older Women , 2000, Drugs & Aging.

[9]  J. Hall,et al.  Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin? , 1999, Gynecologic oncology.

[10]  J. Bomalaski.  The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life. , 1999, Current opinion in obstetrics & gynecology.

[11]  A. Lissoni,et al.  Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Tu,et al.  Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups. , 1998, Gynecologic oncology.

[13]  Mcguire Wp,et al.  Chemotherapy of advanced ovarian cancer. , 1998 .

[14]  C. Kamby,et al.  Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group. , 1998, Gynecologic oncology.

[15]  M. Extermann,et al.  Cancer chemotherapy in the older patient , 1997, Cancer.

[16]  C. L. Edwards,et al.  Gynecologic cancer in the elderly. , 1997, Clinics in geriatric medicine.

[17]  M. Gore,et al.  Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H E Lambert,et al.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Rustin,et al.  Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Riggs.  Rising ovarian cancer mortality in the elderly: a manifestation of differential survival. , 1995, Gynecologic oncology.

[21]  R. Park.  Age‐is it a risk factor in ovarian cancer? , 1994 .

[22]  H. Averette,et al.  National survey of ovarian carcinoma IV: Patterns of care and related survival for older patients , 1994, Cancer.

[23]  C. Cassel,et al.  The aging of the human species. , 1993, Scientific American.

[24]  Ulrich Rendtel,et al.  Editorial , 2014, Journal of basic microbiology.

[25]  R. Yancik,et al.  Ovarian cancer in the elderly: an analysis of Surveillance, Epidemiology, and End Results Program data. , 1986, American journal of obstetrics and gynecology.

[26]  C. Rodenburg,et al.  Chemotherapy in advanced ovarian cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[27]  M. Parmar,et al.  Advanced epithelial ovarian cancer: 1998 consensus statements. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  P. Remington,et al.  Trends in United States ovarian cancer mortality, 1979-1995. , 1999, Obstetrics and gynecology.

[29]  M. Gore,et al.  Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  R Yancik,et al.  Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. , 1993, Cancer.

[31]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[32]  T E Walsh,et al.  Reporting results. , 1969, Archives of otolaryngology.